Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

Prostate Cancer

Free Subscription 24.02.2025 2 Acta Radiol 1 AJR Am J Roentgenol 3 BJU Int 1 BMC Cancer 1 BMC Urol 2 Br J Cancer 1 Br J Radiol 1 Cancer 1 Cancer Lett 2 Clin Cancer Res 1 Eur J Radiol 1 Eur Radiol 1 Eur Urol 3 Int J Urol 2 J Nucl Med 1 Lancet Oncol 1 Nat Rev Urol 1 Oncol Rep 1 PLoS One 5 Prostate 1 Radiol Imaging Cancer

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Radiol

1. LI Y, Zhou X, Zhang X, Zhang M, et al
   Bi-parametric MRI radiomic model for prostate cancer diagnosis: value of intralesional and perilesional radiomics.
   Acta Radiol. 2025 Feb 18:2841851251317646. doi: 10.1177/02841851251317646.
   PubMed         Abstract available
   
   
2. SIROLU S, Seker ME, Alis D, Guroz B, et al
   Assessing the aggressiveness of prostate cancer using ADC and relaxation maps from synthetic MRI.
   Acta Radiol. 2025 Feb 18:2841851251315717. doi: 10.1177/02841851251315717.
   PubMed         Abstract available
   
   

   
   AJR Am J Roentgenol

3. SCHOOTS IG, Haider MA, Punwani S, Padhani AR, et al
   MRI in Prostate Cancer Screening: A Review and Recommendations, From the AJR Special Series on Screening.
   AJR Am J Roentgenol. 2025 Feb 19. doi: 10.2214/AJR.24.32588.
   PubMed         Abstract available
   
   

   
   BJU Int

4. BOESEN L, Norgaard N, Bisbjerg R, Logager V, et al
   Clinical value of contralateral biopsies in men with unilateral MRI foci undergoing targeted biopsy.
   BJU Int. 2025;135:465-472.
   PubMed         Abstract available
   
   
5. MAYOR N, Light A, Silvanto A, Cullen E, et al
   Fluorescence confocal microscopy for margin assessment in prostatectomy: IP8-FLUORESCE study protocol.
   BJU Int. 2025;135:502-509.
   PubMed         Abstract available
   
   
6. ORTNER G, Falkenbach F, Kachanov M, Inderhees T, et al
   External validation of a nomogram for unilateral pelvic lymph node dissection in prostate cancer.
   BJU Int. 2025 Feb 20. doi: 10.1111/bju.16687.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. WEN Y, Zhan S, Wang S, Yang L, et al
   LINC00657 exhibits oncogenic properties in prostate cancer and may serve as a prognostic biomarker in cancer.
   BMC Cancer. 2025;25:314.
   PubMed         Abstract available
   
   

   
   BMC Urol

8. FU Y, Chen J, Zhu X, Ding M, et al
   Roles and therapeutic potential of the SLC family in prostate cancer-literature review.
   BMC Urol. 2025;25:32.
   PubMed         Abstract available
   
   

   
   Br J Cancer

9. LIN SC, Cheng YS, Lin YS, Nguyen TMH, et al
   The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance.
   Br J Cancer. 2025 Feb 16. doi: 10.1038/s41416-025-02938.
   PubMed         Abstract available
   
   
10. O'SULLIVAN JM, Heinrich D, Castro E, George S, et al
    Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.
    Br J Cancer. 2025;132:354-360.
    PubMed         Abstract available
    
    

    
    Br J Radiol

11. LEE KL, Kessler DA, Caglic I, Kuo YH, et al
    Assessing the Performance of ChatGPT and Bard/Gemini Against Radiologists for PI-RADS Classification Based on Prostate Multiparametric MRI Text Reports.
    Br J Radiol. 2024 Nov 13:tqae236. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Cancer

12. NIERENGARTEN MB
    Healthy diet may reduce the risk of low-grade prostate cancer progressing to a higher grade.
    Cancer. 2025;131:e35740.
    PubMed        
    
    

    
    Cancer Lett

13. CHAN HY, Wang Q, Howie A, Bucci J, et al
    Extracellular vesicle biomarkers redefine prostate cancer radiotherapy.
    Cancer Lett. 2025 Feb 18:217568. doi: 10.1016/j.canlet.2025.217568.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

14. GALSKY MD, Autio KA, Cabanski CR, Wentzel K, et al
    Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-3693.
    PubMed         Abstract available
    
    
15. BJARTELL A, Krzyzanowska A, Liu VYT, Tierney M, et al
    Validation of a digital pathology-based multimodal artificial intelligence biomarker in a prospective, real-world prostate cancer cohort treated with prostatectomy.
    Clin Cancer Res. 2025 Feb 21. doi: 10.1158/1078-0432.CCR-24-3656.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

16. TOKUDA B, Yamada K, Kozawa N, Takahata A, et al
    Temporal Evolution of multiparametric magnetic resonance imaging findings following lesion-targeted focal microwave tissue coagulation for localized prostate cancer.
    Eur J Radiol. 2025;185:111995.
    PubMed         Abstract available
    
    

    
    Eur Radiol

17. HAIDER MA
    PI-CAI: a landmark AI study for prostate cancer detection on MRI.
    Eur Radiol. 2025 Feb 17. doi: 10.1007/s00330-025-11454.
    PubMed        
    
    

    
    Eur Urol

18. GILLESSEN S, Tombal B, Turco F, Choudhury A, et al
    Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.
    Eur Urol. 2025;87:285-288.
    PubMed         Abstract available
    
    

    
    Int J Urol

19. IWAMOTO H, Izumi K, Mizokami A
    Editorial Comment on the Overuse of Imaging in Prostate Cancer Staging.
    Int J Urol. 2025 Feb 17. doi: 10.1111/iju.70015.
    PubMed        
    
    
20. HSIEH PF, Naruse J, Yuzuriha S, Umemoto T, et al
    Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer.
    Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70013.
    PubMed         Abstract available
    
    
21. URABE F, Kimura S
    Considerations on the Optimal Imaging for Prostate Cancer Diagnosis.
    Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70016.
    PubMed        
    
    

    
    J Nucl Med

22. KOSTOS L, Buteau JP, Kong G, Tran B, et al
    Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.269252. doi: 10.2967/jnumed.124.269252.
    PubMed         Abstract available
    
    
23. EIFER M, Sutherland DEK, Goncalves I, Buteau JP, et al
    Therapy-Related Myeloid Neoplasms After [(177)Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.
    J Nucl Med. 2025 Feb 20:jnumed.124.268640. doi: 10.2967/jnumed.124.268640.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

24. EMMETT L, Subramaniam S, Crumbaker M, Joshua AM, et al
    Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2025 Feb 12:S1470-2045(25)00009.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

25. LANG P, Vassar M
    Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes.
    Nat Rev Urol. 2025 Feb 18. doi: 10.1038/s41585-025-01008.
    PubMed        
    
    

    
    Oncol Rep

26. GUO X, Li S
    Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).
    Oncol Rep. 2025;53:46.
    PubMed         Abstract available
    
    

    
    PLoS One

27. BELTRAN A, Parker L, Moral-Perez I, Caballero-Romeu JP, et al
    Impact of patients' age and comorbidities on prostate cancer overdiagnosis in clinical practice.
    PLoS One. 2025;20:e0315979.
    PubMed         Abstract available
    
    

    
    Prostate

28. HABAULT J, Franco JL, Ha S, Schneider JA, et al
    In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.
    Prostate. 2025 Feb 16:e24868. doi: 10.1002/pros.24868.
    PubMed         Abstract available
    
    
29. KAMBE T, Kubota M, Yamasaki T, Kawakita M, et al
    Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low-Dose Estramustine in Very High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy.
    Prostate. 2025 Feb 19:e24875. doi: 10.1002/pros.24875.
    PubMed         Abstract available
    
    
30. HACIOGLU MB, Kucukarda A, Gokmen I, Gurbuz AF, et al
    Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization.
    Prostate. 2025 Feb 19. doi: 10.1002/pros.24876.
    PubMed         Abstract available
    
    
31. BRITTON CJ, Andrews JR, Arafa A, Kim Y, et al
    Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single-Institution Pilot Study.
    Prostate. 2025 Feb 20:e24861. doi: 10.1002/pros.24861.
    PubMed         Abstract available
    
    
32. 
    RETRACTION: Stat3 Enhances the Growth of LNCaP Human Prostate Cancer Cells in Intact and Castrated Male Nude Mice.
    Prostate. 2025 Feb 21:e24872. doi: 10.1002/pros.24872.
    PubMed        
    
    

    
    Radiol Imaging Cancer

33. LAI AL, Velaga J, Tay KJ, Hang G, et al
    Multiparametric MRI before and after Focal Therapy for Prostate Cancer: Pearls and Pitfalls for the Reporting Radiologist.
    Radiol Imaging Cancer. 2025;7:e240269.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.